These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

758 related articles for article (PubMed ID: 24615871)

  • 1. The effect of sacral neuromodulation on pudendal nerve function and female sexual function.
    Parnell BA; Howard JF; Geller EJ
    Neurourol Urodyn; 2015 Jun; 34(5):456-60. PubMed ID: 24615871
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Sacral neuromodulation in urology. The emperor's new clothes or effective high-tech medicine?].
    Hoda MR; Fornara P
    Urologe A; 2010 Oct; 49(10):1254-9. PubMed ID: 20859609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sacral nerve stimulation reduces elevated urinary nerve growth factor levels in women with symptomatic detrusor overactivity.
    Shalom DF; Pillalamarri N; Xue X; Kohn N; Lind LR; Winkler HA; Metz CN
    Am J Obstet Gynecol; 2014 Nov; 211(5):561.e1-5. PubMed ID: 25019486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PNE versus 1st stage tined lead procedure: a direct comparison to select the most sensitive test method to identify patients suitable for sacral neuromodulation therapy.
    Leong RK; De Wachter SG; Nieman FH; de Bie RA; van Kerrebroeck PE
    Neurourol Urodyn; 2011 Sep; 30(7):1249-52. PubMed ID: 21404317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of sacral neuromodulation in modern urogynaecology practice: a review of recent literature.
    Tahseen S
    Int Urogynecol J; 2018 Aug; 29(8):1081-1091. PubMed ID: 29302716
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving clinical outcomes for women with overactive bladder or urinary retention symptoms: a comparison of motor response voltages (1-9 V) during Stage 1 sacral neuromodulation.
    Marinkovic SP; Ford JC
    BJU Int; 2018 Sep; 122(3):472-479. PubMed ID: 29637712
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The value of urodynamic tools to guide patient selection in sacral neuromodulation.
    Drossaerts J; Rademakers K; van Koeveringe G; Van Kerrebroeck P
    World J Urol; 2015 Nov; 33(11):1889-95. PubMed ID: 25680936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does sacral nerve stimulation improve global pelvic function in women?
    Jadav AM; Wadhawan H; Jones GL; Wheldon LW; Radley SC; Brown SR
    Colorectal Dis; 2013 Jul; 15(7):848-57. PubMed ID: 23451900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sacral neuromodulation for lower urinary tract dysfunction and impact on erectile function.
    Lombardi G; Mondaini N; Giubilei G; Macchiarella A; Lecconi F; Del Popolo G
    J Sex Med; 2008 Sep; 5(9):2135-40. PubMed ID: 18637993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Sacral neuromodulation in under- and overactive detrusor-quo vadis? : Principles and developments].
    Girtner F; Burger M; Mayr R
    Urologe A; 2019 Jun; 58(6):634-639. PubMed ID: 31139864
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged percutaneous SNM testing does not cause infection-related explanation.
    Amend B; Bedke J; Khalil M; Stenzl A; Sievert KD
    BJU Int; 2013 Mar; 111(3):485-91. PubMed ID: 22738331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Psychological and psychiatric factors as predictors for success in sacral neuromodulation treatment.
    Marcelissen TA; Leong RK; Nieman FH; van Lankveld JJ; van Kerrebroeck PE; de Wachter SG
    BJU Int; 2011 Dec; 108(11):1834-8. PubMed ID: 21810157
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacral neuromodulation in patients with idiopathic overactive bladder after initial botulinum toxin therapy.
    Smits MA; Oerlemans D; Marcelissen TA; Van Kerrebroeck PE; De Wachter SG
    J Urol; 2013 Dec; 190(6):2148-52. PubMed ID: 23872028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results of a prospective, randomized, multicenter study evaluating sacral neuromodulation with InterStim therapy compared to standard medical therapy at 6-months in subjects with mild symptoms of overactive bladder.
    Siegel S; Noblett K; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Berg KC; Kan F; Irwin CP
    Neurourol Urodyn; 2015 Mar; 34(3):224-30. PubMed ID: 24415559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Results of sacral posterior neuromodulation on voiding disorders and impact on sexuality based on a single-center study].
    Ferhi K; Miaadi N; Tanneau Y; Leroi AM; Sibert L; Grise P
    Prog Urol; 2008 Mar; 18(3):160-6. PubMed ID: 18472068
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Impact of Duration of Complaints on Successful Outcome of Sacral Neuromodulation.
    Jairam R; Drossaerts J; van Koeveringe G; van Kerrebroeck P
    Urol Int; 2017; 99(1):51-55. PubMed ID: 28478446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder.
    Noblett K; Siegel S; Mangel J; Griebling TL; Sutherland SE; Bird ET; Comiter C; Culkin D; Bennett J; Zylstra S; Kan F; Berg KC
    Neurourol Urodyn; 2016 Feb; 35(2):246-51. PubMed ID: 25546568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of pulse rate changes on the clinical outcome of sacral neuromodulation.
    Marcelissen TA; Leong RK; Nieman FH; de Bie RA; van Kerrebroeck PE; de Wachter SG
    J Urol; 2011 May; 185(5):1781-5. PubMed ID: 21420118
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacral neuromodulation blocks pudendal inhibition of reflex bladder activity in cats: insight into the efficacy of sacral neuromodulation in Fowler's syndrome.
    Li X; Uy J; Yu M; Li S; Theisen K; Browning J; Shen B; Wang J; Roppolo JR; de Groat WC; Tai C
    Am J Physiol Regul Integr Comp Physiol; 2018 Jan; 314(1):R34-R42. PubMed ID: 28931549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new minimally invasive procedure for pudendal nerve stimulation to treat neurogenic bladder: description of the method and preliminary data.
    Spinelli M; Malaguti S; Giardiello G; Lazzeri M; Tarantola J; Van Den Hombergh U
    Neurourol Urodyn; 2005; 24(4):305-9. PubMed ID: 15977260
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.